

## **TranXenoGen, Inc.**

### **Evaluation Agreement**

TranXenoGen, Inc. (“TranXenoGen”), the avian transgenic company listed on the Alternative Investment Market of the London Stock Exchange (TXN.L) announced today that they have entered into an evaluation agreement with an unnamed biotechnology company. Under the agreement, TranXenoGen will provide the biotechnology company two proprietary chicken embryonic stem cell lines for evaluation in the production of vaccine candidates.

The biotechnology company, which has several therapeutic vaccines for the treatment of infectious diseases in clinical trials, is evaluating a variety of avian cell lines, two of which are TranXenoGen’s. The evaluation is anticipated to be completed during the fourth quarter of 2003.

**George Uveges, President and CEO of TranXenoGen, commented:**

*“The chicken embryonic stem cell lines were developed as part of the Company’s avian stem cell research to improve the efficiency of its avian transgenic platform. The potential use of the Company’s cell lines for vaccine production is an alternative application of the Company’s technology platform”.*

**18 June 2003**

#### **ENQUIRIES:**

**TranXenoGen, Inc.**

**College Hill Associates**

**Tel: 001 508 936 4214**

**Tel: +44 (0) 7457 2020**

George Uveges, President and CEO

Nicholas Nelson

Email: [guveges@tranxenogen.com](mailto:guveges@tranxenogen.com)

#### About TranXenoGen

*TranXenoGen, Inc. (symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company is developing avian transgenic technologies for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.*

**Risk Warning Notice:**

*This press release contains forward-looking statements that can be identified by terminology such as “expects”, “potential”, “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company’s planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.*